2023 Global ESG Double Materiality Assessment Report

This report is a comprehensive document detailing Bristol Myers Squibb's (BMS) 2023 Global ESG Double Materiality Assessment. It outlines the company's engagement with key stakeholder groups to identify the Environmental, Social, and Governance (ESG) topics deemed most significant by these stakeholders. The methodology employed in this assessment was guided by industry best practices and aligned with the Corporate Sustainability Reporting Directive's European Sustainability Reporting Standards. The report summarizes the objectives, approach, and findings of the assessment, which involved input from 170 participants across various internal and external stakeholder groups. Key ESG topics identified include Pricing and Patient Access, Product Innovation, and others, which will inform BMS's business priorities and strategies. The document emphasizes the importance of stakeholder engagement in building trust and aligning business decisions with stakeholder expectations, while also highlighting the need for transparency and effective resource allocation in ESG initiatives.